Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy

Trial Profile

Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; MEDI 6469 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
    • 13 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top